Epidemic Patterns and Effectiveness of Treatment of Tuberculosis Patients with Different Drug Resistance Profiles in the Republic of Tajikistan

The objective: study of the burden and effectiveness of treatment of multiple drug resistant pulmonary tuberculosis (MDR TB) with different chemotherapy regimens in the Republic of Tajikistan.

Subjects and Methods. To achieve this objective, the prevalence of drug resistant tuberculosis in 2009–2020 was studied by analyzing statistical documents on drug resistant tuberculosis, official reporting data from the Center for Medical Statistics and Republican TB Control Center by the Ministry of Health and Population Social Welfare of the Republic of Tajikistan.

Results. The analysis of official statistics indicates a stable trend towards a decrease in tuberculosis incidence from 2014 to 2019, annually on average up to 1% – from 60,8 to 56,5 per 100,000 population. During the pandemic in 2019–2020, this trend increased, according to statistics the incidence made 39.7 per 100,000 population. From 2014 to 2019, tuberculosis mortality also declined steadily from 3,9 to 2,2 per 100,000 population. During the pandemic in 2019–2020, a rapid decline was noted – from 2,2 to 1,4, while in 2020–2022, it decreased from 1,4 to 1,0 per 100,000 population. From 2013 to 2020 treatment success reached 90%. The detection of drug resistant tuberculosis is close to 900 cases per year, and more than 90% of them were covered with treatment. In 2018–2020, successful treatment of drug resistant tuberculosis increased from 72,5% to 80,6% due to the introduction of new and repurposed anti-tuberculosis drugs.

1. Bobokhodzhaev O. I., Mirzoeva F. O., Akhmedov A. Modern ways of detection and diagnostic methods of pulmonary tuberculosis. Vestnik Instituta Poslediplomnogo Obrazovaniya V Sfere Zdravookhraneniya, 2017, no. 1, pp. 91–96. (In Russ.)

2. Burakova M. V. Efficacy of pulmonary tuberculosis chemotherapy in new cases depending on the time of drug resistance detection. Tuberculosis and Lung Diseases, 2017, no. 11 (95), pp. 63–66. (In Russ.)

3. Vasilyeva I. A. The effect of different TB drugs and antimicrobial agents on the efficacy of treatment of tuberculosis patients with multiple drug resistance. Tuberculosis and Lung Diseases, 2017, no. 10 (95), pp. 9–15. (In Russ.)

4. Vasilyeva I. A., Belilovsky E. M., Borisov S. E., Sterlikov S. A. Multiple drug resistant tuberculosis in the world and Russian Federation. Tuberculosis and Lung Diseases, 2017, no. 11 (95), pp. 5–17. (In Russ.)

5. Vasilyeva I. A., Testov V. V., Sterlikov S. A. Tuberculosis situation in the years of the COVID-19 pandemic – 2020–2021. Tuberculosis and Lung Diseases, 2022, no. 100 (3), pp. 6–12. (In Russ.)

6. Ivanova D. A., Borisov S. E. Discontinue or wait?: indications for cancellation of anti-tuberculosis drugs due to adverse reactions. Tuberculosis and Lung Diseases, 2018, no. 2 (96), pp. 47–54. (In Russ.)

7. Makhmudova P. U., Zakirova K. A. Efficiency of treatment of patients with drug-resistant forms of pulmonary tuberculosis in the Republic of Tajikistan. Vestnik Avitsenny, 2018, no. 2–3, pp. 235–239. (In Russ.)

8. Panova L. V., Ovsyankina E. S., Lovacheva O. V., Sadovnikova S. S., Viechelli E. A., Khiteva A. Yu. Personalized treatment of pulmonary MDR/XDR tuberculosis in adolescents. Tuberculosis and Lung Diseases, 2018, no. 2 (96), pp. 55–63. (In Russ.)

9. Sirodzhidinova U. Yu., Bobohodzhaev O. I., Dustmatova Z. Sh., Mirzoeva F. O., Pirov K. I. Analysis of tuberculosis situation in the Republic of Tajikistan. Tuberculosis and Lung Diseases, 2015, no. 2, pp. 39–40. (In Russ.)

10. Skryagina E. M., Gurevich G. L., Solodovnikova V. V., Dyusmikeeva M. I., Setkina S. B., Zhurkin D. M. Experience of treating multiple/extensive drug resistant tuberculosis with new regimens in Belarus Republic. Tuberculosis and Lung Diseases, 2018, no. 8 (96), pp. 5–14. (In Russ.)

11. Ahmad N. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: An individual patient data meta-analysis. Lancet, 2018, no. 392, pp. 821–834.

12. Bobokhojaev O. I. Long term results of 10 years of observation of cured cases of pulmonary tuberculosis. J. Pulmonol. Respir. Res., 2022, no. 6, pp. 007–011. ISSN 2639-9954 DOI: 10.29328/journal.jprr.1001036

13. Guglielmetti L., Hewison C., Avaliani Z., Hughes J., Kiria N., Lomtadze N., Ndjeka N., Setkina S., Shabangu A. Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries. International Journal Tuberculoses and Lung Diseases, 2017, no. 21, pp. 167–174.

14. Jo Y., Mirzoeva F., Chry M., Bobokhojaev O., et al. Standardized framework for evaluating costs of active case finding programs: An analysis of two programs in Cambodia and Tajikistan. PLOS ONE, 2020, no. 15 (1), e0228216. https://doi.org/10.1371/journal.pone.0228216

15. Rajabzoda A., Mahmudova P., Soliev A., Ziyoyeva S., Bobokhojaev O. Implementation of active Drug Safety Monitoring (aDSM) for monitoring adverse events in DR-TB treatment with bedaquiline in the Republic of Tajikistan. International Journal Tuberculosis and Lung Diseases, 2017, no. 21 (11), pp. 688–13.

16. Trebucq A. Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade of Evidence. Journal Clinical Medicine, 2020, no. 9 (1), p. 55.

17. Von Groote-Bidlingmaier F. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Lancet Respiratory Medicine, 2019, no. 7 (3), рр. 249–259.

18. WHO: Global TB Report 2021. – Geneva. – 2022. Available at: https://www.who.int/publications/i/item/9789240037021 [ Accessed Feb 10, 2023]